MilkLab Shrinks Its Annual Loss
MilkLab Shrinks Its Annual Loss
Noumi (ASX:NOU), the company behind MilkLab and a range of plant-based dairy products, formerly known as Freedom Foods, has shown promising progress with a sharp reduction in its annual loss for the year ending June 30.
MilkLab和一系列植物性乳製品（前身爲Freedom Foods）背後的公司Noumi（澳大利亞證券交易所股票代碼：NOU）取得了可喜的進展，截至6月30日的年度虧損大幅減少。
The company reported a loss of $46.9 million, reflecting the ongoing success of its turnaround strategy, implemented after a near-collapse situation two years prior. This loss represents just a quarter of the staggering $161 million deficit from the previous year.
該公司報告虧損4,690萬美元，這反映了其轉型戰略的持續成功，該戰略是在兩年前瀕臨崩潰之後實施的。這一虧損僅佔去年驚人的1.61億美元赤字的四分之一。
Annual revenue saw a noteworthy uptick of 5.6%, reaching nearly $552 million, driven by growing consumer interest in its dairy and nutritional offerings, particularly the MilkLab line of almond milk.
年收入顯著增長5.6％，達到近5.52億美元，這得益於消費者對其乳製品和營養產品，尤其是MilkLab系列杏仁奶的興趣與日俱增。
This shift was mirrored in the company's adjusted operating EBITDA, a non-traditional measure of profit, which surged to $30.4 million for the fiscal year 2022-23, compared to a modest $7 million in the preceding year.
這一轉變反映在公司調整後的營業息稅折舊攤銷前利潤（一種非傳統的利潤衡量標準）中，該利潤激增至2022-23財年的3,040萬美元，而上一年爲700萬美元。
The reported net loss incorporates non-cash impairments totaling $8.2 million related to the valuation of plant and equipment in the Dairy and Nutritionals segment, as well as $39.5 million in adjustments to the fair value of convertible notes.
報告的淨虧損包括與乳製品和營養品板塊工廠和設備估值相關的總額爲820萬美元的非現金減值，以及對可轉換票據公允價值的3,950萬美元調整。
Directors clarified, "Excluding these non-cash items, the Company reported a positive net profit after tax of approximately $0.8 million, compared to a loss of $80.3 million in FY22."
董事們澄清說：“不包括這些非現金項目，公司報告的稅後淨利潤約爲80萬美元，而22財年的虧損爲8,030萬美元。”
Directors attributed the 10.8% revenue growth of the Consumer Nutritionals portfolio to investments in brands like Vital Strength and the development of new products.
董事們將消費營養品投資組合收入增長10.8％歸因於對Vital Strength等品牌的投資和新產品的開發。
The company maintained a slight increase in cash at bank and undrawn facilities, amounting to $36.6 million, ensuring sufficient liquidity for day-to-day operations in line with current market conditions and expectations.
該公司維持銀行和未提取貸款的現金略有增加，達到3,660萬美元，確保了符合當前市場狀況和預期的日常運營所需的充足流動性。
CEO Michael Perich expressed in an ASX filing, "The past year marked significant progress for Noumi as we advanced through our three-phase Reset, Transform, and Grow strategy in the face of occasional headwinds. Our focus on executing our plan has yielded tangible accomplishments on the path to sustainable, long-term growth."
首席執行官邁克爾·佩裏奇（Michael Perich）在澳大利亞證券交易所的一份文件中表示：“在過去的一年中，Noumi取得了重大進展，因爲面對偶爾出現的不利因素，我們推進了三階段的重置、轉型和增長戰略。我們專注於執行計劃，在可持續的長期增長道路上取得了切實的成就。”
Perich continued, "In addition to the continuous expansion of our Plant-based Milks business, exemplified by another record earnings performance of our flagship brand, Milklab, we are particularly pleased with the substantial turnaround in Dairy and Nutritionals."
Perich繼續說：“除了我們的植物性牛奶業務持續擴張（我們的旗艦品牌Milklab的收益表現再創歷史新高）外，我們對乳製品和營養品的重大轉變感到特別滿意。”
He noted, "Dairy and Nutritionals, which recorded an operating loss in FY22, achieved positive adjusted operating EBITDA in the latter half of FY23, representing a significant stride towards long-term sustainability."
他指出：“乳製品和營養品在2022財年錄得營業虧損，在23財年下半年實現了調整後的營業息稅折舊攤銷前利潤爲正，這是朝着長期可持續發展邁出的重要一步。”
Perich concluded, "Looking ahead, our priorities include enhancing distribution for the Plant-based Milks business both domestically and internationally, and solidifying the recovery in Dairy and Nutritionals. Despite challenges posed by the ongoing dislocation of the Australian farmgate milk price from global prices, we remain committed to adapting to the market's demands."
Perich總結說：“展望未來，我們的優先事項包括加強植物性牛奶業務在國內和國際上的分銷，以及鞏固乳製品和營養品的復甦。儘管澳大利亞農場牛奶價格與全球價格的持續脫節帶來了挑戰，但我們仍然致力於適應市場的需求。”
譯文內容由第三人軟體翻譯。